News & Events
2012
-
October 26, 2012License Agreement of SGLT2 Inhibitor "CSG452" in Japan
-
June 6, 2012A consolidated subsidiary of Mitsubishi Tanabe Pharma, Tai Tien Pharmaceuticals Co., Ltd., started marketing Livalo (pitavastatin), a hypercholesterolemia treatment agent (an HMG-CoA reductase inhibitor), in Taiwan on June 1, 2012.
A regulatory approval was obtained in January 2011. -
May 9, 2012A consolidated subsidiary of Mitsubishi Tanabe Pharma，P.T. Tanabe Indonesia，started marketing Livalo (pitavastatin)，a hypercholesterolemia treatment agent (an HMG-CoA reductase inhibitor)，in Indonesia on May 1，2012.
The launch comes after P.T. Tanabe Indonesia received regulatory approval in November 2011. -
February 20, 2012Eli Lilly has introduced Redevant (pitavastatin), an HMG-CoA reductase inhibitor for lowering cholesterol, in Mexico this month. The launch comes after the product received approval in July 2011 from the country's Ministry of Health.